Back to Newsroom

Data to be Presented at ASHG 2014 Show That Miscarriage Analysis by Chromosomal Microarray Yields a Successful Result in More Than 85% of Cases

IRVINE, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced data from a comprehensive, multi-year analysis of products of conception (POC) testing by chromosomal microarray analysis (CMA) showing that CMA yields a successful result in more than 85% of cases. Trilochan Sahoo, M.D., Director of cytogenetics at CombiMatrix, will present results at the American Society of Human Genetics (ASHG)’s64th Annual Meeting on Monday, October 20, 2014 in San Diego, California.

Click here to read more